TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2/10/23 19:56 | 2/9/23 | EXEL | Exelixis, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Feldbaum Carl B | CA | D | M.d | 252 | 6.30 | 0 | 40 | 19 | D | ||||||||||||||||
2/10/23 19:56 | 2/9/23 | EXEL | Exelixis, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Feldbaum Carl B | CA | D | S.d | -711 | 17.78 | 0 | -40 | -68 | 19 | D | |||||||||||||||
2/24/22 20:20 | 2/22/22 | EXEL | Exelixis, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Feldbaum Carl B | CA | D | M.d | 63 | 3.13 | 0 | 20 | 9 | D | ||||||||||||||||
2/24/22 20:20 | 2/22/22 | EXEL | Exelixis, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Feldbaum Carl B | CA | D | S.d | -390 | 19.49 | 0 | -20 | -70 | 9 | D | |||||||||||||||
11/23/21 20:11 | 11/19/21 | EXEL | Exelixis, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Feldbaum Carl B | CA | D | M.d | 63 | 3.13 | 0 | 20 | 9 | D | ||||||||||||||||
11/23/21 20:11 | 11/19/21 | EXEL | Exelixis, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Feldbaum Carl B | CA | D | S.d | -352 | 17.62 | 0 | -20 | -70 | 9 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |